Remove Hypertension Remove Preserved Ejection Fraction Remove Pulmonary
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Right ventricular function and anemia in heart failure with preserved ejection fraction

Frontiers in Cardiovascular Medicine

The level of hemoglobin (Hb) had a weak negative linear correlation with NT-pro-BNP (log-transform, r = 0.30, P < 0.0001) and a positively correlation with the tricuspid annular plane systolic excursion (TAPSE)/pulmonary arterial systolic pressure (PASP) ratio (r = 0.44, P < 0.0001).

article thumbnail

Heart Failure With Preserved Ejection Fraction Phenotype Is Associated With Early Symptom Onset in Aortic Stenosis and Residual Symptoms After Transcatheter Aortic Valve Implantation

Journal of the American Heart Association

BackgroundAortic stenosis can lead to cardiac adaptations and symptoms similar to heart failure with preserved ejection fraction. Journal of the American Heart Association, Ahead of Print. Methods and ResultsThis retrospective cohort study included 469 patients with moderate aortic stenosis.

article thumbnail

Top 10: Must-reads from the Month of May

DAIC

Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 10. Geisinger Enrolls First Patient in Amyloid Cardiomyopathy Trial 9. Tenax Therapeutics Announces New U.S.

article thumbnail

Right Ventricular?Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association

BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes. Journal of the American Heart Association, Ahead of Print.

article thumbnail

Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP?HF II trial

European Journal of Heart Failure

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Pulmonary vascular resistance at rest and exercise decreased with higher BMI.

article thumbnail

Tadalafil for Combined Post-/Precapillary PH Treatment in HFpEF

American College of Cardiology

What is the safety and efficacy of tadalafil in patients with heart failure with preserved ejection fraction (HFpEF) and combined postcapillary and precapillary pulmonary hypertension (CpcPH)?